Cargando…
The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study
BACKGROUND: HCV transmission remains high in people who inject drugs (PWID) in Montréal. New direct-acting antivirals (DAAs), highly effective and more tolerable than previous regimens, make a “Treatment as Prevention” (TasP) strategy more feasible. This study assesses how improvements in the cascad...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320702/ https://www.ncbi.nlm.nih.gov/pubmed/28222681 http://dx.doi.org/10.1186/s12879-017-2256-5 |
_version_ | 1782509587866320896 |
---|---|
author | Cousien, Anthony Leclerc, Pascale Morissette, Carole Bruneau, Julie Roy, Élise Tran, Viet Chi Yazdanpanah, Yazdan Cox, Joseph |
author_facet | Cousien, Anthony Leclerc, Pascale Morissette, Carole Bruneau, Julie Roy, Élise Tran, Viet Chi Yazdanpanah, Yazdan Cox, Joseph |
author_sort | Cousien, Anthony |
collection | PubMed |
description | BACKGROUND: HCV transmission remains high in people who inject drugs (PWID) in Montréal. New direct-acting antivirals (DAAs), highly effective and more tolerable than previous regimens, make a “Treatment as Prevention” (TasP) strategy more feasible. This study assesses how improvements in the cascade of care could impact hepatitis C burden among PWID in Montréal. METHODS: We used a dynamic model to simulate HCV incidence and prevalence after 10 years, and cirrhosis complications after 10 and 40 years. Eight scenarios of improved cascade of care were examined. RESULTS: Using a baseline incidence and prevalence of 22.1/100 person-years (PY) and 53.1%, implementing the current cascade of care using DAAs would lead to HCV incidence and prevalence estimates at 10 years of 9.4/100PY and 55.8%, respectively. Increasing the treatment initiation rate from 5%/year initially to 20%/year resulted in large decreases in incidence (6.4/100PY), prevalence (36.6%), and cirrhosis complications (−18%/-37% after 10/40 years). When restricting treatment to fibrosis level ≥ F2 instead of F0 (reference scenario), such decreases in HCV occurrence were unreachable. Improving the whole cascade of care led to the greatest effect by halving both the incidence and prevalence at 10 years, and the number of cirrhosis complications after 40 years. CONCLUSIONS: The current level of treatment access in Montréal is limiting a massive decrease in hepatitis C burden among PWID. A substantial treatment scale-up, regardless of fibrosis level, is necessary. While improving the rest of the cascade of care is necessary to optimize a TasP strategy and control the HCV epidemic, a treatment scale-up is first needed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2256-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5320702 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53207022017-02-24 The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study Cousien, Anthony Leclerc, Pascale Morissette, Carole Bruneau, Julie Roy, Élise Tran, Viet Chi Yazdanpanah, Yazdan Cox, Joseph BMC Infect Dis Research Article BACKGROUND: HCV transmission remains high in people who inject drugs (PWID) in Montréal. New direct-acting antivirals (DAAs), highly effective and more tolerable than previous regimens, make a “Treatment as Prevention” (TasP) strategy more feasible. This study assesses how improvements in the cascade of care could impact hepatitis C burden among PWID in Montréal. METHODS: We used a dynamic model to simulate HCV incidence and prevalence after 10 years, and cirrhosis complications after 10 and 40 years. Eight scenarios of improved cascade of care were examined. RESULTS: Using a baseline incidence and prevalence of 22.1/100 person-years (PY) and 53.1%, implementing the current cascade of care using DAAs would lead to HCV incidence and prevalence estimates at 10 years of 9.4/100PY and 55.8%, respectively. Increasing the treatment initiation rate from 5%/year initially to 20%/year resulted in large decreases in incidence (6.4/100PY), prevalence (36.6%), and cirrhosis complications (−18%/-37% after 10/40 years). When restricting treatment to fibrosis level ≥ F2 instead of F0 (reference scenario), such decreases in HCV occurrence were unreachable. Improving the whole cascade of care led to the greatest effect by halving both the incidence and prevalence at 10 years, and the number of cirrhosis complications after 40 years. CONCLUSIONS: The current level of treatment access in Montréal is limiting a massive decrease in hepatitis C burden among PWID. A substantial treatment scale-up, regardless of fibrosis level, is necessary. While improving the rest of the cascade of care is necessary to optimize a TasP strategy and control the HCV epidemic, a treatment scale-up is first needed. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2256-5) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-21 /pmc/articles/PMC5320702/ /pubmed/28222681 http://dx.doi.org/10.1186/s12879-017-2256-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Cousien, Anthony Leclerc, Pascale Morissette, Carole Bruneau, Julie Roy, Élise Tran, Viet Chi Yazdanpanah, Yazdan Cox, Joseph The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
title | The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
title_full | The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
title_fullStr | The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
title_full_unstemmed | The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
title_short | The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study |
title_sort | need for treatment scale-up to impact hcv transmission in people who inject drugs in montréal, canada: a modelling study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320702/ https://www.ncbi.nlm.nih.gov/pubmed/28222681 http://dx.doi.org/10.1186/s12879-017-2256-5 |
work_keys_str_mv | AT cousienanthony theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT leclercpascale theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT morissettecarole theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT bruneaujulie theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT royelise theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT tranvietchi theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT yazdanpanahyazdan theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT coxjoseph theneedfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT cousienanthony needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT leclercpascale needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT morissettecarole needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT bruneaujulie needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT royelise needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT tranvietchi needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT yazdanpanahyazdan needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy AT coxjoseph needfortreatmentscaleuptoimpacthcvtransmissioninpeoplewhoinjectdrugsinmontrealcanadaamodellingstudy |